COVID-19 MESSAGE FROM BMMSA

Our first priority is the health, wellness and safety of everyone who walks through our doors.

Bryn Mawr Medical Specialists Association is open for medically necessary office visits and procedures only. BMMSA as a corporation is taking all necessary precautions and following public health safety guidelines in regards to the COVID-19 pandemic.

TeleMedicine appointments are now available. Please contact your physicians office for eligibility, additional information, and with any concerns or questions.

As per order of the Commonwealth of Pennsylvania, any person entering our office building is required to wear a face mask at all times. Patients will not be permitted to enter the building without a face mask.

All patients should expect to be phone screened by Bryn Mawr Medical Specialists Association staff for COVID-19 symptoms or exposures prior to their appointment and again upon arrival. Patients should also expect to be temperature screened upon arrival in the office.

If your answer to any of the following questions is “Yes”, we ask that you call to reschedule your appointment.

In the past 14 days, have you developed any fever, cough or shortness of breath?
In the past 14 days, have you developed any of the following new symptoms?

  • Body aches or muscle pains?
  • Chills or repeated shaking with chills?
  • Headache?
  • Sore throat?
  • New loss of taste or of smell?
  • Have you, or anyone you have close contact with, been recently referred for COVID-19 testing?

For the safety of our staff and other patients, patient family members or companions are not permitted at this time to accompany patients to their appointments (unless medically necessary or the patient is a minor). Bryn Mawr Medical Specialists Association respectfully asks family members or companions to wait outside or safely in their vehicle.

We encourage all of our patients to visit the CDC website and Main Line Health COVID-19 Response website to read more about everyday preventative measures and for the most up to date guidance regarding the Coronavirus (COVID-19). If you are concerned that you may have the Coronavirus (COVID-19), please contact your local Health Departments.

If you have any questions regarding our policy and your appointment, please call your doctor’s office.

John G. Devlin, M.D.

Hematology/Oncology

Specialties

  • Hematology

    Board Certified in 2007

  • Oncology

    Board Certified in 2008

  • Internal Medicine

    Board Certified in 2004

Location

Bryn Mawr Medical Arts Pavilion
825 Old Lancaster Road
Suite 440
Bryn Mawr, PA 19010
Phone: (610) 525-4511
Fax: (610) 525-8561

Education & Training

Medical School

Temple University School of Medicine

Residency

Temple University Hospital

Fellowships

  • Fox Chase Cancer Center
  • Temple University Hospital

Affiliations

  • Bryn Mawr Hospital – On staff since 2007
  • Lankenau Hospital – On staff since 2007
  • Paoli Hospital – On staff since 2007

Clinical/Dept. Titles

  • Principal Investigator for Main Line Health System, for Alliance Oncology Group, 2019-present
  • Vice-Chair, Main Line Health System Cancer Committee (INCP), 2015 – present
  • Member, Research Review Committee, MLHS, 2015 – present
  • Member, MLHS Center for Clinical Cancer Research, 2015 – present
  • Associate Principal Investigator, Main Line Health System CCOP/NCORP, 2013 – present
  • At-large Member, Medical Executive Committee, Main Line Health System, July 2013 – 2015
  • Campus Chief in Hematology/Oncology, Bryn Mawr Hospital, 2012 – present
  • At-large Member, Medical Operations Committee, Bryn Mawr Hospital, July 2011 – July 2013
  • Director, Clinical Laboratory, Bryn Mawr Medical Specialists Associates, March 2009 – 2012
  • Member, Institutional Review Board, Bryn Mawr Hospital, April 2009 – 2019
  • Ad-hoc Member, Ethics Committee, Bryn Mawr Hospital, January 2009 – present
  • Member, Cancer Committee, Bryn Mawr Hospital, Sept 2007 – present

Recent Clinical Studies Published

  • Simone C, Devlin JG, Singhal S, Langer CJ. Adenoid Cystic Carcinoma of the Lung. Textbook of Uncommon Cancer 5th edition. Raghavan D, Brecher ML, Johnson D, et al. (editors). John Wiley and Sons, 2017, pp.315-326.
  • Devlin JG, Langer CJ. Combined modality treatment of laryngeal squamous cell carcinoma.Expert Rev Anticancer Ther 2007 Mar;7(3):331-350.
  • Devlin JG, Langer CJ. The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS-2 patients. Clin Adv Hematol Oncol. 2007 Mar;5(3):216-33.
  • Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clin Lung Cancer 2007 Mar;8(5):319-26.
  • Devlin JG, Langer CJ. Salvage vinorelbine (VNR) in the 2nd to 4th line setting in advanced nonsmall cell lung cancer (NSCLC) : a retrospective review at the Fox Chase Cancer Center (FCCC). J Clin Oncol 2006 Annual ASCO Meeting Proceedings (Post-meeting edition), Vol 24, No. 18S (June 20 supplement), 2006:17072.
  • Devlin JG, Langer CJ. Ch. 28 -Adenoid Cystic Carcinoma of the Lung. In: Textbook of Uncommon Cancer 3rd edition. Raghavan D, Brecher ML, Johnson D, et al. (editors). John Wiley and Sons, 2006, pp.321-328.
  • Devlin JG, Odze RD, Cheng JD. Ch. 30 – “Uncommon Cancers of the Esophagus.” In: Textbook of Uncommon Cancer, 3rd edition. Raghavan D, Brecher ML, Johnson D, et al. (editors). John Wiley and Sons, 2006, pp.337-351.
  • Devlin JG, Rubin RN. Case in Point: Sudden One-sided Weakness in a Young Woman.Consultant 2006;46(6):617-619.
  • Devlin JG, Sherman EJ. Combined modality treatment of squamous cell cancer of the head and neck. Clin Adv Hematol Oncol 2005 May;3(5):373-381.

Current Memberships and Activities

American Society of Clinical Oncology
American Sociey of Hematology
Sigma XI – National Research
PA Medical Society

Hematology/Oncology

Browse available departments: